Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life. (29th August 2022)

• Record Type: Journal Article
• Authors: Nelson, Bryan S; Tierney, Camlin; Persaud, Deborah; Jao, Jennifer; Cotton, Mark F; Bryson, Yvonne; Coletti, Anne; Ruel, Theodore D; Spector, Stephen A; Reding, Christina; Bacon, Kira; Costello, Diane; Perlowski, Charlotte; Santos Cruz, Maria Leticia; Kosgei, Josphat; Majji, Sai; Yin, Dwight E; Jean-Philippe, Patrick; Chadwick, Ellen G
• Is Part Of: Clinical infectious diseases. Volume 76:Number 3(2023)
• Page Start: e744
• Page End: e747
• Publication Date: 2022-08-29
• Subjects: Pneumocystis jirovecii pneumonia -- cotrimoxazole -- neonatal -- HIV -- CD4; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac695
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: : We followed 54 infants with in utero HIV after initiating very early antiretroviral treatment. At weeks 24 and 48, ≥80% had CD4 ≥1500 cells/mm 3 and CD4% ≥25%. Routine Pneumocystis jirovecii pneumonia prophylaxis in the first year of life may not be necessary for all very early treated infants. Clinical Trials Registration: NCT02140255.